From our survey

What FDA review settles, and leaves open, for St. Charles doubters

If the word "ketamine" makes you raise an eyebrow, you are in good company, and you are asking a fair question. What, exactly, separates a treatment that has been through federal review from one that is simply being offered?

That question turned out to matter a great deal to the people we surveyed. In June 2026 our poll put a question to 443 Midwest adults, St. Charles neighbors among them: how heavily would FDA approval count in trying a ketamine-based depression treatment? For 19 percent it would decide the matter, for 40 percent it would be big, together 59 percent. Some weight, 27 percent. No weight, 14 percent. All of these are final, validated figures.

So a skeptic who wants to know what has been approved is asking what most neighbors would ask. This piece lays the options side by side so you can see what the approval label covers, and just as important, what it leaves open.

Why doubt is a reasonable starting point

Mention ketamine therapy for depression or PTSD to our respondents and most bristled a little. About one in five, 21 percent, called it skepticism, 9 percent something more negative, while cautious but open led every other answer at 34 percent.

That is not a region of believers or opponents. It is a region of people who want proof first, which is the instinct this comparison is written for.

The options, side by side

Option one: esketamine nasal spray (Spravato)

• Approval status: The one ketamine-family product the FDA has approved for depression, in adults whose depression has resisted other treatment.
• Where it happens: Only in a certified healthcare setting. You take the spray on site, remain for supervised observation, and ride home with someone else. Brain Recovery Centers describes what those supervised Spravato visits involve.
• Oversight: Distribution runs through a federal safety program that restricts which settings can give it and requires monitoring after every dose.
• Coverage: Because it carries an approval, many health plans will consider it, usually after a prior authorization that documents which treatments have already been tried.
• What approval leaves out: Whether it suits you, which turns on your history and is a clinician's call.

Option two: IV ketamine infusions at a clinic

• Approval status: Plain ketamine holds its approval as an anesthetic, so a depression infusion is off-label: an approved drug used beyond its label.
• Where it happens: In a clinic, typically with monitoring during and after the infusion.
• Oversight: Protocols, dosing, and staffing vary from one clinic to the next. Off-label prescribing is legal and common in medicine, but there is no single approved regimen that every clinic follows.
• Coverage: Often paid out of pocket, since off-label uses are less likely to be covered. Ask before you book.
• What the missing approval means: Not that it is unsafe, only that this use skipped formal review, so ask more about the clinic.

Option three: at-home ketamine through telehealth

• Approval status: Off-label. This is the grayest of the three.
• Where it happens: In your own home, often after a video visit, without a clinician physically in the room.
• Oversight: Far less direct supervision than either clinic option.
• Coverage: Commonly cash pay.
• What to know: It is not Spravato, whatever the marketing implies.

A drug-free comparison point: TMS

This is a device, not a drug: magnetic pulses aimed at mood circuits, with FDA clearance for depression. Only about a quarter of our respondents, 25 percent, knew it, while 64 percent wanted a drug-free choice. If your skepticism is less about ketamine specifically and more about adding another medication, TMS is worth asking about in the same conversation.

What approval actually settles

An FDA approval means the agency reviewed evidence for one use, in one population, given one way, and concluded the benefits outweigh the risks under those conditions. For esketamine, that includes the supervised setting. The approval and the monitoring rules come as a package.

That package answers three questions a St. Charles skeptic might ask:

• Has this been studied for depression, or is someone improvising? For the approved nasal spray, it has been studied for the indications on its label.
• Is anyone watching while I take it? Yes, by rule, every time.
• Will my insurance even look at it? Approval makes that conversation possible, though not certain.

What approval leaves open

Approval is a floor, not a promise of results, mild side effects, or a well-run clinic. Nor are off-label options reckless; plenty of standard care is off-label.

The useful move for a skeptic is to ask the same questions of every option, regardless of its label:

• What exactly is the drug, the dose, and the route?
• Who is monitoring me, and what are they trained to watch for?
• Who responds, and how, if a session goes badly?
• How will we know, in measurable terms, whether it is helping?
• What will it cost me, and is any of it covered?

The person to bring this to

Our survey pointed clearly at where these conversations should happen. Asked who could talk them into trying it, 74 percent of respondents pointed to their own doctor and 2 percent to an ad. For a doubtful reader in St. Charles County, the next step is not more reading. It is putting this comparison in front of your primary doctor or a psychiatrist and asking which, if any, of these fits your situation.

Treat this page as background, never as medical advice; a clinician who has gone over your history decides whether esketamine or any listed option fits.

If you are carrying thoughts of ending your life, do not hold them until a scheduled visit. A trained Suicide and Crisis Lifeline counselor answers 988, by text or by phone, on any day and at any hour.

Methodology

Pollfish placed survey 395586438 with members of its consumer panel and ended collection June 23, 2026. Its 443 completes came from people aged 18 to 64 across Missouri, Kansas, Illinois, Nebraska, Ohio, Oklahoma, Iowa, Minnesota, Wisconsin and Indiana. Pollfish's data-quality validation is done, and the numbers are final. The survey was commissioned and funded by this article's publisher.